| A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer C Hatzis, L Pusztai, V Valero, DJ Booser, L Esserman, A Lluch, T Vidaurre, ... Jama 305 (18), 1873-1881, 2011 | 649 | 2011 |
| Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system E Andreopoulou, LY Yang, KM Rangel, JM Reuben, L Hsu, ... International journal of cancer 130 (7), 1590-1597, 2012 | 291 | 2012 |
| Circulating tumor cells and [18F] fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer U De Giorgi, V Valero, E Rohren, S Dawood, NT Ueno, MC Miller, ... J Clin Oncol 27 (20), 3303-3311, 2009 | 171 | 2009 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 167 | 2022 |
| Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy SJ Luen, R Salgado, MV Dieci, A Vingiani, G Curigliano, RE Gould, ... Annals of Oncology 30 (2), 236-242, 2019 | 166 | 2019 |
| Detection of minimal residual disease in blood and bone marrow in early stage breast cancer S Krishnamurthy, M Cristofanilli, B Singh, J Reuben, H Gao, EN Cohen, ... Cancer 116 (14), 3330-3337, 2010 | 147 | 2010 |
| Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast … N Juul, Z Szallasi, AC Eklund, Q Li, RA Burrell, M Gerlinger, V Valero, ... The lancet oncology 11 (4), 358-365, 2010 | 145 | 2010 |
| Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy A Giordano, M Giuliano, M De Laurentiis, G Arpino, S Jackson, BC Handy, ... Annals of oncology 23 (5), 1144-1150, 2012 | 131 | 2012 |
| Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells M Mego, U De Giorgi, S Dawood, X Wang, V Valero, E Andreopoulou, ... International journal of cancer 129 (2), 417-423, 2011 | 131 | 2011 |
| SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer BV Sinn, C Fu, R Lau, J Litton, TH Tsai, R Murthy, A Tam, E Andreopoulou, ... NPJ breast cancer 5 (1), 16, 2019 | 106 | 2019 |
| Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer E Andreopoulou, D Gaiotti, E Kim, A Downey, D Mirchandani, A Hamilton, ... Annals of oncology 18 (4), 716-721, 2007 | 105 | 2007 |
| Therapies for triple negative breast cancer E Andreopoulou, SJ Schweber, JA Sparano, HM McDaid Expert opinion on pharmacotherapy 16 (7), 983-998, 2015 | 102 | 2015 |
| An overview of the status of imaging screening technology for breast cancer JA Smith, E Andreopoulou Annals of Oncology 15, i18-i26, 2004 | 91 | 2004 |
| A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK … K Kalinsky, MK Accordino, C Chiuzan, PS Mundi, MS Trivedi, Y Novik, ... Journal of Clinical Oncology 40 (17_suppl), LBA1004-LBA1004, 2022 | 90 | 2022 |
| Chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer: an overview E Andreopoulou, JA Sparano Current breast cancer reports 5, 42-50, 2013 | 89 | 2013 |
| Eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer (ENHANCE 1): a phase Ib/II study SM Tolaney, K Kalinsky, VG Kaklamani, DR D'Adamo, G Aktan, ML Tsai, ... Clinical Cancer Research 27 (11), 3061-3068, 2021 | 81 | 2021 |
| Inhibition of EZH2 catalytic activity selectively targets a metastatic subpopulation in triple-negative breast cancer S Yomtoubian, SB Lee, A Verma, F Izzo, G Markowitz, H Choi, L Cerchietti, ... Cell reports 30 (3), 755-770. e6, 2020 | 81 | 2020 |
| A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer Y Tu, DL Hershman, K Bhalla, W Fiskus, CM Pellegrino, E Andreopoulou, ... Breast cancer research and treatment 146, 145-152, 2014 | 69 | 2014 |
| Treatment of uterine sarcoma at the Royal Marsden Hospital from 1974 to 1998 L Livi, E Andreopoulou, N Shah, F Paiar, P Blake, I Judson, C Harmer Clinical Oncology 16 (4), 261-268, 2004 | 64 | 2004 |
| Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study MA Dimopoulos, M Papadopoulou, E Andreopoulou, C Papadimitriou, ... Gynecologic oncology 70 (1), 70-74, 1998 | 64 | 1998 |
